The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, according to results presented in a Hot Line session at ESC Congress 2026.

Oral anticoagulant therapy lowered the risk of adverse clinical events compared with no anticoagulation in patients with atrial fibrillation at intermediate stroke risk, according to results from the SINGLE-AF trial presented in a Hot Line session at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

Chronic kidney disease (CKD) is a major health burden affecting approximately one in 10 adults globally. Even with improved treatments, many patients continue to experience worsening kidney function, resulting in the need for dialysis or transplantation. Oxidative stress and mitochondrial dysfunction have long been suspected to contribute to CKD, but direct evidence linking these processes to disease development has been limited.

New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2) estimates that the number of people living with type 1 diabetes (T1D) worldwide will increase by 29%, from 9.4 million in 2025 to 12.1 million in 2049. In addition, the number of new cases per year is estimated to increase by 14% during this period.

Major new research from the University of Sydney has found that physiotherapist-led care significantly reduced emergency department waiting and treatment times for people with back pain, fractures, dislocations and other musculoskeletal conditions. The randomized controlled trial recruited 1,491 patients who presented to five emergency departments in NSW between November 2023 and March 2025. The findings are published in the journal BMJ Open.